MediGene, Johns Hopkins join on HPV vax research

MediGene, a Martinsried/Munich-based biotech, and The Johns Hopkins University will work together to create HPV vaccine candidates using the German firm's AAVLP platform. The preclinical program uses adeno-associated viruses as the basis for the vaccine and antigenic peptides to induce specific antibody reactions. MediGene hopes the platform can be used for viral infection and cancer vaccines as well. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.